Nezulcitinib (TD-0903) is an inhaled pan-Janus kinase (JAK) inhibitor which is lung-selective and has the potential for COVID-19 associated acute lung injury and impaired oxygenation. As of June 2021, it was reported that nezulcitinib fails to meet Phase II goals in Covid-19.

纯度：≥98%

CAS：2412496-23-0